keyword
MENU ▼
Read by QxMD icon Read
search

dutasteride

keyword
https://www.readbyqxmd.com/read/28817871/re-a-prospective-longitudinal-survey-of-erectile-function-status-in-symptomatic-benign-prostatic-hyperplasia-patients-treated-with-dutasteride
#1
Steven A Kaplan
No abstract text is available yet for this article.
September 2017: Journal of Urology
https://www.readbyqxmd.com/read/28800206/relative-bioavailability-of-fixed-dose-combinations-of-tamsulosin-and-dutasteride-results-from-2-randomized-trials-in-healthy-male-volunteers
#2
Olivia Burns, John Zhu, Michael J Manyak, Ramiya Ravindranath, Fariba Koosha, Nazneen Haque, Sally Chung
The relative bioavailabilities of dutasteride/tamsulosin hydrochloride 0.5 mg/0.2 mg fixed-dose combination (FDC) capsules compared with coadministered reference products (1 dutasteride 0.5-mg capsule [Avodart(®) ] + 1 tamsulosin hydrochloride 0.2-mg orally disintegrating tablet [Harnal D(®) ]) were investigated in 2 clinical trials under fasted and fed conditions (ClinicalTrials.gov NCT02184585 and NCT02509104). Both trials were open-label, randomized, single-dose, crossover studies in healthy male adults aged 18-65 years...
August 11, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28789947/impact-of-5%C3%AE-reductase-inhibitors-on-disease-reclassification-among-men-on-active-surveillance-for-localized-prostate-cancer-with-favorable-features
#3
Charles Dai, Vishnu Ganesan, Joseph Zabell, Yaw A Nyame, Nima Almassi, Daniel J Greene, Daniel Hettel, Chad Reichard, Samuel C Haywood, Hans Arora, Anna Zampini, Alice Crane, Jianbo Li, Ahmed Elshafei, Cristina Magi-Galluzzi, Robert J Stein, Khaled Fareed, Michael Gong, J Stephen Jones, Eric A Klein, Andrew J Stephenson
PURPOSE: To determine the effect of 5α-reductase inhibitors (5-ARI) on disease reclassification in men with prostate cancer optimally selected for active surveillance (AS). MATERIALS AND METHODS: A retrospective review identified 635 patients on AS between 2002-2015. Patients with favorable cancer features on repeat biopsy, defined as absence of Gleason upgrading, were included in the cohort. Patients were stratified by those who did or did not receive finasteride/dutasteride within 1 year of diagnosis...
August 5, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28789926/commentary-on-redirecting-abiraterone-metabolism-to-fine-tune-prostate-cancer-anti-androgen-therapy-li-z-alyamani-m-li-j-rogacki-k-abazeed-m-upadhyay-sk-balk-sp-taplin-me-auchus-rj-sharifi-n-nature-2016-may-25-533-7604-547-51
#4
Byron H Lee
Abiraterone blocks androgen synthesis and prolongs survival in patients with castration-resistant prostate cancer, which is otherwise driven by intratumoral androgen synthesis. Abiraterone is metabolized in patients to Δ(4)-abiraterone (D4A), which has even greater antitumour activity and is structurally similar to endogenous steroidal 5α-reductase substrates, such as testosterone. Here, we show that D4A is converted to at least three 5α-reduced and three 5β-reduced metabolites in human serum. The initial 5α-reduced metabolite, 3-keto-5α-abiraterone, is present at higher concentrations than D4A in patients with prostate cancer taking abiraterone, and is an androgen receptor agonist, which promotes prostate cancer progression...
August 5, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28765837/the-impact-of-finasteride-and-dutasteride-treatments-on-proliferation-apoptosis-androgen-receptor-5%C3%AE-reductase-1-and-5%C3%AE-reductase-2-in-tramp-mouse-prostates
#5
Alexander B Opoku-Acheampong, Jamie N Henningson, Brian L Lindshield
BACKGROUND: Previously, we studied the effect of finasteride- or dutasteride-containing diets in male C57BL/6 TRAMP x FVB mice. Pre (6 weeks of age) and post (12 weeks of age) groups received finasteride or dutasteride to determine the efficacy of these pharmaceuticals on prostate cancer (PCa) development in male C57BL/6 TRAMP x FVB mice. Post-Dutasteride treatment was more effective than Pre-Dutasteride treatment, and dutasteride treatments were more effective than finasteride treatments in decreasing prostatic intraepithelial neoplasia (PIN) progression and PCa development...
July 2017: Heliyon
https://www.readbyqxmd.com/read/28743526/change-in-psa-concentration-in-men-with-psa-2-5-ng-ml-taking-low-dose-finasteride-or-dutasteride-for-male-androgenetic-alopecia
#6
Ho Won Kang, Myeong Heon Chae, Su Hyun Park, Sung Pil Seo, Won Tae Kim, Yong-June Kim, Seok-Joong Yun, Sang-Cheol Lee, Tae Young Yoon, Wun-Jae Kim
PURPOSE: This retrospective cohort study aimed to assess the effect on PSA concentrations of low-dose finasteride or dutasteride treatment for male androgenetic alopecia whose baseline serum PSA < 2.5 ng/mL. PATIENTS AND METHODS: The cohort consisted of 1,379 consecutive male patients who were treated for androgenetic alopecia with finateride 1.25 mg daily or dutasteride 0.5 mg every 3 days in 2002-2012 and underwent PSA measurements at baseline and at least once thereafter...
July 22, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28710320/correction-a-phase-ii-trial-of-abiraterone-combined-with-dutasteride-for-men-with-metastatic-castration-resistant-prostate-cancer
#7
(no author information available yet)
No abstract text is available yet for this article.
July 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28704587/effects-of-testosterone-administration-and-its-5-alpha-reduction-on-parenchymal-organ-volumes-in-healthy-young-men-findings-from-a-dose-response-trial
#8
T Gagliano-Jucá, E R Tang, S Bhasin, K M Pencina, S Anderson, H Jara, Z Li, K Melamud, S L Coleman, A Aakil, R R Almeida, G Huang, T G Travison, T W Storer, S Basaria
Animal data shows that testosterone administration increases the volume of some parenchymal organs. However, the effects of exogenous testosterone on solid abdominal organs in humans remain unknown. The present study evaluated the effects of testosterone administration on the volume of liver, spleen and kidneys in a dose-response trial. Young healthy men aged 18-50 years participating in the 5α-Reductase (5aR) Trial. All participants received monthly injections of 7.5 mg leuprolide acetate to suppress endogenous testosterone secretion and weekly injections of 50, 125, 300 or 600 mg of testosterone enanthate, and were randomized to receive either 2...
July 13, 2017: Andrology
https://www.readbyqxmd.com/read/28670847/reclassification-of-prostate-cancer-risk-using-sequentially-identified-snps-results-from-the-reduce-trial
#9
Haitao Chen, Rong Na, Vignesh T Packiam, Carly A Conran, Deke Jiang, Sha Tao, Hongjie Yu, Xiaoling Lin, Wei Meng, S Lilly Zheng, Charles B Brendler, Brian T Helfand, Jianfeng Xu
BACKGROUND: Although the clinical validity of risk-associated single nucleotide polymorphisms (SNPs) for assessment of disease susceptibility has been consistently established, risk reclassification from increasing numbers of implicated risk-associated SNPs raises concern that it is premature for clinical use. Our objective is to assess the degree and impact of risk reclassification with the increasing number of SNPs. METHODS: A total of 3239 patients from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial were included...
July 2, 2017: Prostate
https://www.readbyqxmd.com/read/28656603/a-genetic-variant-near-gata3-implicated-in-inherited-susceptibility-and-etiology-of-benign-prostatic-hyperplasia-bph-and-lower-urinary-tract-symptoms-luts
#10
Rong Na, Brian T Helfand, Haitao Chen, Carly A Conran, Susan E Crawford, Simon W Hayward, Teuvo L J Tammela, Judy Hoffman-Bolton, Siqun L Zheng, Patrick C Walsh, Johanna Schleutker, Elizabeth A Platz, William B Isaacs, Jianfeng Xu
BACKGROUND: Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) are common conditions. Little is known about their etiologies except that studies have suggested a substantial heritable component. Our objective is to provide a comprehensive, genome-wide evaluation of inherited risks and possible mechanisms of etiology in BPH. METHODS: We performed a three-stage, genome-wide association study (GWAS) of men from three independent populations, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial, the CLUE II cohort, and a Finnish hospital-based population...
August 2017: Prostate
https://www.readbyqxmd.com/read/28650680/transurethral-resection-of-prostate-and-bleeding-a-prospective-randomized-double-blind-placebo-controlled-trial-to-see-the-efficacy-of-short-term-use-of-finasteride-and-dutasteride-on-operative-blood-loss-and-prostatic-microvessel-density
#11
Ankur Bansal, Aditi Arora
OBJECTIVE: The aim of this study was to determine the efficacy of short-duration use of finasteride and dutasteride before transurethral resection of the prostate (TURP) on intraoperative blood loss and microvessel density (MVD) of prostate stroma and suburethral tissues in benign prostatic hyperplasia (BPH). METHODS: This study includes 450 patients who were planned for TURP. They were prospectively randomized into three groups (150 patients each). Group 1 received placebo, group 2 received finasteride, 5 mg per day, and group 3 patients received dutasteride, 0...
June 26, 2017: Journal of Endourology
https://www.readbyqxmd.com/read/28632494/long-term-dutasteride-therapy-in-men-with-benign-prostatic-hyperplasia-alters-glucose-and-lipid-profiles-and-increases-severity-of-erectile-dysfunction
#12
Abdulmaged Traish, Karim Sultan Haider, Gheorghe Doros, Ahmad Haider
Background Dutasteride has been successfully used in treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). However, dutasteride inhibits 5α-reductase type 1 and type 2 enzymes and may compromises glucocorticoids and androgen metabolism and alters metabolic function resulting in undesirable metabolic and sexual adverse side effects. Aim The aim of this study was to investigate the long-term adverse effects of dutasteride therapy in men with BPH on: i) blood glucose, ii) glycated hemoglobin (HbA1c), iii) low density lipoprotein-cholesterol (LDL-C); high density lipoprotein-cholesterol (HDL-C) and total cholesterol (TC), iv) testosterone (T), v) liver alanine and aspartate aminotransferases (ALT and AST) and vi) erectile dysfunction (ED)...
June 21, 2017: Hormone Molecular Biology and Clinical Investigation
https://www.readbyqxmd.com/read/28602645/synthesis-and-comprehensive-structural-and-physicochemical-characterization-of-dutasteride-hydrochloride-hydrate-solvates
#13
Marcin Górecki, Alicja Dziedzic, Roman Luboradzki, Anna Ostaszewska, Jadwiga Frelek, Wojciech J Szczepek
Four crystalline dutasteride hydrochloride hydrate solvates containing respectively methanol, ethanol, acetone and acetonitrile molecules were obtained. All samples were characterized by extensive spectroscopic analysis with infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC) and (1)H as well as (13)C NMR techniques. For three solvates, i.e. methanol, ethanol and acetone solvates, the single crystal X-ray diffraction (SCXRD) experiments were possible, and their respective crystal and molecular structures were determined...
June 9, 2017: Steroids
https://www.readbyqxmd.com/read/28585572/the-combination-of-histological-prostate-atrophy-and-inflammation-is-associated-with-lower-risk-of-prostate-cancer-in-biopsy-specimens
#14
D M Moreira, D M de O Freitas, J C Nickel, G L Andriole, R Castro-Santamaria, S J Freedland
BACKGROUND: To evaluate whether the presence of both prostate atrophy (PA) and chronic prostate inflammation (CPI) in the same biopsy and in the same biopsy core are associated with prostate cancer (PCa) risk and grade in repeat biopsies. METHODS: Retrospective analyses of 6132 men who were 50-75 years old undergoing 2-year repeat prostate biopsy after a negative baseline biopsy for PCa in the REduction by DUtasteride of prostate Cancer Events (REDUCE) study. PA, CPI and PCa were determined by central pathology...
June 6, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28523355/mri-findings-in-men-on-active-surveillance-for-prostate-cancer-does-dutasteride-make-mri-visible-lesions-less-conspicuous-results-from-a-placebo-controlled-randomised-clinical-trial
#15
Francesco Giganti, Caroline M Moore, Nicola L Robertson, Neil McCartan, Charles Jameson, Simon R J Bott, Mathias Winkler, Giulio Gambarota, Brandon Whitcher, Ramiro Castro, Mark Emberton, Clare Allen, Alex Kirkham
OBJECTIVES: To investigate changes in the Apparent Diffusion Coefficient (ADC) using diffusion-weighted imaging (DWI) in men on active surveillance for prostate cancer taking dutasteride 0.5 mg or placebo. METHODS: We analysed 37 men, randomised to 6 months of daily dutasteride (n = 18) or placebo (n = 19), undergoing 3T multi-parametric Magnetic Resonance Imaging (mpMRI) scans at baseline and 6 months. Images were reviewed blind to treatment allocation and clinical information...
May 18, 2017: European Radiology
https://www.readbyqxmd.com/read/28499730/effects-of-withdrawing-%C3%AE-1-blocker-from-combination-therapy-with-%C3%AE-1-blocker-and-5%C3%AE-reductase-inhibitor-in-patients-with-lower-urinary-tract-symptoms-suggestive-of-benign-prostatic-hyperplasia-a-prospective-and-comparative-trial-using-urodynamics
#16
Yoshihisa Matsukawa, Shun Takai, Yasuhito Funahashi, Tsuyoshi Majima, Masashi Kato, Tokunori Yamamoto, Momokazu Gotoh
PURPOSE: We compared the effects on lower urinary tract symptoms and bladder outlet obstruction of combination therapy with α1-blocker and 5α-reductase inhibitor or a switch to 5α-reductase inhibitor monotherapy. We determined the factors influencing changes in lower urinary tract symptoms after α1-blocker withdrawal. MATERIALS AND METHODS: A total of 140 outpatients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia received combination therapy with silodosin 8 mg per day and dutasteride 0...
May 10, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28487578/5%C3%AE-reductase-inhibitors-for-treatment-of-benign-prostatic-hyperplasia-a-systematic-review-and-meta-analysis
#17
REVIEW
Jennifer E J Jun, Angus Kinkade, Anthony C H Tung, Aaron M Tejani
BACKGROUND: Finasteride and dutasteride are competitive inhibitors of 5α-reductase enzymes and are commonly used to treat symptomatic benign prostatic hyperplasia (BPH). OBJECTIVE: To compare the efficacy and safety of finasteride and dutasteride in terms of clinically important outcomes. DATA SOURCES: A literature search was performed using the search terms "prostatic hyperplasia", "prostatic hypertrophy", "dutasteride", "finasteride", "quality of life", "adverse drug reaction", and "mortality"...
March 2017: Canadian Journal of Hospital Pharmacy
https://www.readbyqxmd.com/read/28487295/statin-use-serum-lipids-and-prostate-inflammation-in-men-with-a-negative-prostate-biopsy-results-from-the-reduce-trial
#18
Emma H Allott, Lauren E Howard, Adriana C Vidal, Daniel M Moreira, Ramiro Castro-Santamaria, Gerald L Andriole, Stephen J Freedland
Statin use is associated with lower advanced prostate cancer risk. In addition to cholesterol lowering, statins have systemic anti-inflammatory properties. However, their effect on histologic prostate inflammation is not well understood, particularly among men at increased prostate cancer risk but with a negative prostate biopsy. We examined associations between serum lipid levels, statin use, and histologic prostate inflammation using data from 6,655 men with a negative baseline prostate biopsy in the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial...
June 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/28466585/efficacy-and-safety-of-combination-therapy-with-tamsulosin-dutasteride-and-imidafenacin-for-the-management-of-overactive-bladder-symptoms-associated-with-benign-prostatic-hyperplasia-a-multicenter-randomized-open-label-controlled-trial-direct-study
#19
Tomonori Yamanishi, Hirotaka Asakura, Narihito Seki, Shoji Tokunaga
OBJECTIVES: To evaluate the efficacy and safety of a combination therapy with dutasteride and imidafenacin in patients with benign prostatic hyperplasia and persistent overactive bladder symptoms. METHODS: A total of 163 patients presenting an enlarged prostate (volume >30 mL) and persistent overactive bladder symptoms despite at least 8 weeks of tamsulosin were randomized to receive tamsulosin and dutasteride, or tamsulosin, dutasteride and imidafenacin at a 1:1 ratio...
July 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28453908/sexual-dysfunction-in-subjects-treated-with-inhibitors-of-5%C3%AE-reductase-for-benign-prostatic-hyperplasia-a-comprehensive-review-and-meta-analysis
#20
REVIEW
G Corona, G Tirabassi, D Santi, E Maseroli, M Gacci, M Dicuio, A Sforza, E Mannucci, M Maggi
Despite their efficacy in the treatment of benign prostatic hyperplasia, the popularity of inhibitors of 5α-reductase (5ARIs) is limited by their association with adverse sexual side effects. The aim of this study was to review and meta-analyze currently available randomized clinical trials evaluating the rate of sexual side effects in men treated with 5ARIs. An extensive Medline Embase and Cochrane search was performed including the following words: 'finasteride', 'dutasteride', 'benign prostatic hyperplasia'...
April 28, 2017: Andrology
keyword
keyword
43774
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"